Shorter individuals twice as likely to develop esophageal cancer
the ONA take:
According to a new study published in the journal Clinical Gastroenterology and Hepatology, researchers at Fred Hutchinson Cancer Research Center in Seattle, Washington, have found that taller individuals are less likely to develop Barrett's esophagus and esophageal cancer than shorter individuals.
For the study, the researchers analyzed data from 14 studies within the International Barrett's and Esophageal Adenocarcinoma Consortium (BEACON). They found that those in the lowest quartile of height, or men under 5'7" and women under 5'2", were approximately twice as likely as those in the highest quartile of height, or men taller than 6' and women taller than 5'5", to have esophageal cancer or Barrett's esophagus.
Bases on analyses, results were consistent among various other factors, including age, body mass index, education, gastroesophageal reflux disease (GERD) symptoms, sex, and smoking. Researchers suggest that height may be able to be used as a risk factors to identify patients with a higher risk of developing Barrett's esophagus or esophageal cancer. Of note, the relationship between height and esophageal cancer observed in this study is the opposite of what has been observed in breast, colorectal, and prostate cancers.
Taller individuals are less likely to develop Barrett's esophagus and esophageal cancer.
A new study has observed that tall people are less likely to suffer from esophageal cancer as compared to short people.
The study conducted a large pooled analysis using data from 14 population-based epidemiologic studies within the International Barrett's and Esophageal Adenocarcinoma Consortium (BEACON), including 1,000 cases of esophageal cancer and twice as many cases of Barrett's esophagus, and twice as many controls.
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Immunotherapy and the Future of Prostate Cancer Treatment
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- E-cigarettes and Replacement Nicotine Therapy Safer Than Tobacco Use
- Patients With Urologic Cancer Need Psycho-oncologic Support to Manage High Stress
- Lung Cancer Screening Rates Low Among Present and Former Smokers
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Patients Undergoing Multiple Systemic Therapies for Metastatic Prostate Cancer Expect a Cure
- FDA Grants Priority Review to Ceritinib for First-line Treatment of ALK+ NSCLC
- Overall Health Worse in African American Men Undergoing Active Surveillance For Prostate Cancer
- Clinical Benefit of Simtuzumab Inconsistent for Myelofibrosis
- Follow-up Rates in Active Surveillance for Prostate Cancer Higher in University-Based vs Safety-Net Hospitals
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|